BLOG

pharmas almanac

What key indicators do you look at to predict the future of this industry?

At Xalud, we’re developing a non-viral plasmid DNA platform that has the potential to change the paradigm in chronic inflammatory diseases by creating a gene therapy for the masses and not just for rare diseases. We have a pipeline with broad potential for our proprietary platform, including several programs in development, and we look forward to being part of this new wave in gene therapy.